Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339426 · ClinicalTrials.gov registry record · Phase 2
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04339426: Clinical Trial Phase 2 study, sponsored by HonorHealth Research Institute.
NCT04339426 is a Phase 2 study that was terminated before completion, run by HonorHealth Research Institute. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04339426, a Phase 2 study, was terminated before completion, sponsored by HonorHealth Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.
Primary Outcome
Virology cure rate defined as the percentage of patients who achieved undetectable COVID-19 viral load via serology testing.
Interventions
- DRUG Atovaquone/Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 2 |
Why NCT04339426 stopped before completion
NCT04339426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Atovaquone/Azithromycin is the first listed.
NCT04339426 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04339426 about?
NCT04339426 is a clinical study titled "Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection". This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.
What is the current status of trial NCT04339426?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2020-04-20. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT04339426?
The interventions under investigation include: Atovaquone/Azithromycin (DRUG).
Who is sponsoring clinical trial NCT04339426?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04339426's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI